Literature DB >> 32295908

Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.

Gwo-Yu Chuang1, Yen-Ting Lai1, Jeffrey C Boyington1, Cheng Cheng1, Hui Geng1, Sandeep Narpala1, Reda Rawi1, Stephen D Schmidt1, Yaroslav Tsybovsky2, Raffaello Verardi1, Kai Xu1, Yongping Yang1, Baoshan Zhang1, Michael Chambers1, Anita Changela1, Angela R Corrigan1, Rui Kong1, Adam S Olia1, Li Ou1, Edward K Sarfo1, Shuishu Wang1, Winston Wu1, Nicole A Doria-Rose1, Adrian B McDermott1, John R Mascola3, Peter D Kwong3.   

Abstract

HIV-1 envelope (Env) trimers, stabilized in a prefusion-closed conformation, can elicit humoral responses capable of neutralizing HIV-1 strains closely matched in sequence to the immunizing strain. One strategy to increase elicited neutralization breadth involves vaccine priming of immune responses against a target site of vulnerability, followed by vaccine boosting of these responses with prefusion-closed Env trimers. This strategy has succeeded at the fusion peptide (FP) site of vulnerability in eliciting cross-clade neutralizing responses in standard vaccine-test animals. However, the breadth and potency of the elicited responses have been less than optimal. Here, we identify three mutations (3mut), Met302, Leu320, and Pro329, that stabilize the apex of the Env trimer in a prefusion-closed conformation and show antigenically, structurally, and immunogenically that combining 3mut with other approaches (e.g., repair and stabilize and glycine-helix breaking) yields well-behaved clade C-Env trimers capable of boosting the breadth of FP-directed responses. Crystal structures of these trimers confirmed prefusion-closed apexes stabilized by hydrophobic patches contributed by Met302 and Leu320, with Pro329 assuming canonically restricted dihedral angles. We substituted the N-terminal eight residues of FP (FP8, residues 512 to 519) of these trimers with the second most prevalent FP8 sequence (FP8v2, AVGLGAVF) and observed a 3mut-stabilized consensus clade C-Env trimer with FP8v2 to boost the breadth elicited in guinea pigs of FP-directed responses induced by immunogens containing the most prevalent FP8 sequence (FP8v1, AVGIGAVF). Overall, 3mut can stabilize the Env trimer apex, and the resultant apex-stabilized Env trimers can be used to expand the neutralization breadth elicited against the FP site of vulnerability.IMPORTANCE A major hurdle to the development of an effective HIV-1 vaccine is the elicitation of serum responses capable of neutralizing circulating strains of HIV, which are extraordinarily diverse in sequence and often highly neutralization resistant. Recently, we showed how sera with 20 to 30% neutralization breadth could, nevertheless, be elicited in standard vaccine test animals by priming with the most prevalent N-terminal 8 residues of the HIV-1 fusion peptide (FP8), followed by boosting with a stabilized BG505-envelope (Env) trimer. Here, we show that subsequent boosting with a 3mut-apex-stabilized consensus C-Env trimer, modified to have the second most prevalent FP8 sequence, elicits higher neutralization breadth than that induced by continued boosting with the stabilized BG505-Env trimer. With increased neutralizing breadth elicited by boosting with a heterologous trimer containing the second most prevalent FP8 sequence, the fusion peptide-directed immune-focusing approach moves a step closer toward realizing an effective HIV-1 vaccine regimen.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; fusion peptide; neutralization; vaccine

Mesh:

Substances:

Year:  2020        PMID: 32295908      PMCID: PMC7307166          DOI: 10.1128/JVI.00074-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  EMAN2: an extensible image processing suite for electron microscopy.

Authors:  Guang Tang; Liwei Peng; Philip R Baldwin; Deepinder S Mann; Wen Jiang; Ian Rees; Steven J Ludtke
Journal:  J Struct Biol       Date:  2006-06-08       Impact factor: 2.867

2.  Highly conserved protective epitopes on influenza B viruses.

Authors:  Cyrille Dreyfus; Nick S Laursen; Ted Kwaks; David Zuijdgeest; Reza Khayat; Damian C Ekiert; Jeong Hyun Lee; Zoltan Metlagel; Miriam V Bujny; Mandy Jongeneelen; Remko van der Vlugt; Mohammed Lamrani; Hans J W M Korse; Eric Geelen; Özcan Sahin; Martijn Sieuwerts; Just P J Brakenhoff; Ronald Vogels; Olive T W Li; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Andrew B Ward; Ian A Wilson; Jaap Goudsmit; Robert H E Friesen
Journal:  Science       Date:  2012-08-09       Impact factor: 47.728

3.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Authors:  Jesper Pallesen; Nianshuang Wang; Kizzmekia S Corbett; Daniel Wrapp; Robert N Kirchdoerfer; Hannah L Turner; Christopher A Cottrell; Michelle M Becker; Lingshu Wang; Wei Shi; Wing-Pui Kong; Erica L Andres; Arminja N Kettenbach; Mark R Denison; James D Chappell; Barney S Graham; Andrew B Ward; Jason S McLellan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-14       Impact factor: 11.205

4.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

Authors:  Jason S McLellan; Marie Pancera; Chris Carrico; Jason Gorman; Jean-Philippe Julien; Reza Khayat; Robert Louder; Robert Pejchal; Mallika Sastry; Kaifan Dai; Sijy O'Dell; Nikita Patel; Syed Shahzad-ul-Hussan; Yongping Yang; Baoshan Zhang; Tongqing Zhou; Jiang Zhu; Jeffrey C Boyington; Gwo-Yu Chuang; Devan Diwanji; Ivelin Georgiev; Young Do Kwon; Doyung Lee; Mark K Louder; Stephanie Moquin; Stephen D Schmidt; Zhi-Yong Yang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Dennis R Burton; Wayne C Koff; Laura M Walker; Sanjay Phogat; Richard Wyatt; Jared Orwenyo; Lai-Xi Wang; James Arthos; Carole A Bewley; John R Mascola; Gary J Nabel; William R Schief; Andrew B Ward; Ian A Wilson; Peter D Kwong
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

5.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

Authors:  Daniel A Calarese; Christopher N Scanlan; Michael B Zwick; Songpon Deechongkit; Yusuke Mimura; Renate Kunert; Ping Zhu; Mark R Wormald; Robyn L Stanfield; Kenneth H Roux; Jeffery W Kelly; Pauline M Rudd; Raymond A Dwek; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

7.  Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.

Authors:  Daniel W Kulp; Jon M Steichen; Matthias Pauthner; Xiaozhen Hu; Torben Schiffner; Alessia Liguori; Christopher A Cottrell; Colin Havenar-Daughton; Gabriel Ozorowski; Erik Georgeson; Oleksandr Kalyuzhniy; Jordan R Willis; Michael Kubitz; Yumiko Adachi; Samantha M Reiss; Mia Shin; Natalia de Val; Andrew B Ward; Shane Crotty; Dennis R Burton; William R Schief
Journal:  Nat Commun       Date:  2017-11-21       Impact factor: 14.919

8.  Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET.

Authors:  Maolin Lu; Xiaochu Ma; Luis R Castillo-Menendez; Jason Gorman; Nirmin Alsahafi; Utz Ermel; Daniel S Terry; Michael Chambers; Dongjun Peng; Baoshan Zhang; Tongqing Zhou; Nick Reichard; Kevin Wang; Jonathan R Grover; Brennan P Carman; Matthew R Gardner; Ivana Nikić-Spiegel; Akihiro Sugawara; James Arthos; Edward A Lemke; Amos B Smith; Michael Farzan; Cameron Abrams; James B Munro; Adrian B McDermott; Andrés Finzi; Peter D Kwong; Scott C Blanchard; Joseph G Sodroski; Walther Mothes
Journal:  Nature       Date:  2019-04-10       Impact factor: 49.962

9.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

10.  Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.

Authors:  Torben Schiffner; Jesper Pallesen; Rebecca A Russell; Jonathan Dodd; Natalia de Val; Celia C LaBranche; David Montefiori; Georgia D Tomaras; Xiaoying Shen; Scarlett L Harris; Amin E Moghaddam; Oleksandr Kalyuzhniy; Rogier W Sanders; Laura E McCoy; John P Moore; Andrew B Ward; Quentin J Sattentau
Journal:  PLoS Pathog       Date:  2018-05-10       Impact factor: 6.823

View more
  5 in total

1.  A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation.

Authors:  Krishana Gulla; Nicole Cibelli; Jonathan W Cooper; Haley C Fuller; Zachary Schneiderman; Sara Witter; Yaqiu Zhang; Anita Changela; Hui Geng; Christian Hatcher; Sandeep Narpala; Yaroslav Tsybovsky; Baoshan Zhang; Adrian B McDermott; Peter D Kwong; Daniel B Gowetski
Journal:  Vaccine       Date:  2021-05-18       Impact factor: 4.169

2.  Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens.

Authors:  Emma T Crooks; Francisco Almanza; Alessio D'Addabbo; Erika Duggan; Jinsong Zhang; Kshitij Wagh; Huihui Mou; Joel D Allen; Alyssa Thomas; Keiko Osawa; Bette T Korber; Yaroslav Tsybovsky; Evan Cale; John Nolan; Max Crispin; Laurent K Verkoczy; James M Binley
Journal:  PLoS Pathog       Date:  2021-10-22       Impact factor: 7.464

3.  Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.

Authors:  Katherine V Houser; Martin R Gaudinski; Myra Happe; Sandeep Narpala; Raffaello Verardi; Edward K Sarfo; Angela R Corrigan; Richard Wu; Ro Shauna Rothwell; Laura Novik; Cynthia S Hendel; Ingelise J Gordon; Nina M Berkowitz; Cora Trelles Cartagena; Alicia T Widge; Emily E Coates; Larisa Strom; Somia Hickman; Michelle Conan-Cibotti; Sandra Vazquez; Olga Trofymenko; Sarah Plummer; Judy Stein; Christopher L Case; Martha Nason; Andrea Biju; Danealle K Parchment; Anita Changela; Cheng Cheng; Hongying Duan; Hui Geng; I-Ting Teng; Tongqing Zhou; Sarah O'Connell; Chris Barry; Kevin Carlton; Jason G Gall; Britta Flach; Nicole A Doria-Rose; Barney S Graham; Richard A Koup; Adrian B McDermott; John R Mascola; Peter D Kwong; Julie E Ledgerwood
Journal:  EClinicalMedicine       Date:  2022-06-01

4.  Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria.

Authors:  Joseph R Francica; Wei Shi; Gwo-Yu Chuang; Steven J Chen; Lais Da Silva Pereira; S Katie Farney; Barbara J Flynn; Li Ou; Tyler Stephens; Yaroslav Tsybovsky; Lawrence T Wang; Alexander Anderson; Zoltan Beck; Marlon Dillon; Azza H Idris; Nicholas Hurlburt; Tracy Liu; Baoshan Zhang; Carl R Alving; Gary R Matyas; Marie Pancera; John R Mascola; Peter D Kwong; Robert A Seder
Journal:  Vaccines (Basel)       Date:  2021-03-18

5.  Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface.

Authors:  Alba Torrents de la Peña; Iván Del Moral Sánchez; Judith A Burger; Ilja Bontjer; Gözde Isik; Dirk Eggink; Marit J van Gils; Rogier W Sanders
Journal:  J Virol       Date:  2021-09-29       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.